SIGNIFOR LAR 60 MG Իսրայել - անգլերեն - Ministry of Health

signifor lar 60 mg

medison pharma ltd - pasireotide as embonate - powder and solvent for suspension for injection - pasireotide as embonate 60 mg/vial - pasireotide - signifor lar is indicated for the treatment of adult patients with acromegaly for whom surgery is not an option or has not been curative and who are inadequately controlled on treatment with another somatostatin analogue.

SIGNIFOR LAR 10 MG Իսրայել - անգլերեն - Ministry of Health

signifor lar 10 mg

medison pharma ltd - pasireotide as pamoate - powder and solvent for suspension for injection - pasireotide as pamoate 10 mg/vial - pasireotide - treatment of adult patients with cushing’s disease for whom surgery is not an option or for whom surgery has failed.

SIGNIFOR LAR 30 MG Իսրայել - անգլերեն - Ministry of Health

signifor lar 30 mg

medison pharma ltd - pasireotide as pamoate - powder and solvent for suspension for injection - pasireotide as pamoate 30 mg/vial - pasireotide - treatment of adult patients with cushing’s disease for whom surgery is not an option or for whom surgery has failed.

Sandostatin 100 mcg/ml Solution for Injection Հորդանան - անգլերեն - JFDA (Jordan Food & Drug Administration - المؤسسة العامة للغذاء والدواء)

sandostatin 100 mcg/ml solution for injection

شركة مستودع الأدوية الأردني - the jordan drugstore co - octreotide 100 mcg/ml - 100 mcg/ml

SANDOSTATIN 0.2 MGML Իսրայել - անգլերեն - Ministry of Health

sandostatin 0.2 mgml

novartis israel ltd - octreotide - solution for injection / infusion - octreotide 0.2 mg/ml - octreotide - octreotide - prevention of complications following pancreatic surgery. symptomatic control and reduction of gh and igf-1plasma levels in patients with acromegaly who are inadequately controlled by surgery or radiotherapy. sandostatin treatment is also indicated for acromegalic patients unfit or unwilling to undergo surgery or in the interim period until radiotherapy becomes fully effective. relief of symptoms associated with functional gastroenteropancreatic endocrine tumours: - carcinoid tumours with features of the carcinoid syndrome - vipomas - glucagonomas - gastrinomas / zollinger-ellison syndrome usually in conjunction with proton pump inhibitors or h2- antagonist therapy - insulinomas for pre-operative control of hypoglycaemia and for maintenance therapy - grfomas. sandostatin is not an antitumour therapy and is not curative in these patients.emergency management of bleeding gastro-oesophageal varices secondary to cirrhosis in combination with specific therapy such as endoscopic sclerothera

OCTREOTIDE 0.1 Mg/Ml Solution for Injection Իռլանդիա - անգլերեն - HPRA (Health Products Regulatory Authority)

octreotide 0.1 mg/ml solution for injection

hospira uk limited - octreotide acetate - solution for injection - 0.1 mg/ml - somatostatin and analogues

OCTREOTIDE 0.2 Mg/Ml Solution for Injection Իռլանդիա - անգլերեն - HPRA (Health Products Regulatory Authority)

octreotide 0.2 mg/ml solution for injection

hospira uk limited - octreotide acetate - solution for injection - 0.2 mg/ml - somatostatin and analogues

OCTREOTIDE 500 Microgram/ML Solution for Injection Իռլանդիա - անգլերեն - HPRA (Health Products Regulatory Authority)

octreotide 500 microgram/ml solution for injection

fresenius kabi limited - octreotide acetate - solution for injection - 500 microgram/ml - somatostatin and analogues

OCTREOTIDE 0.5 Mg/Ml Solution for Injection Իռլանդիա - անգլերեն - HPRA (Health Products Regulatory Authority)

octreotide 0.5 mg/ml solution for injection

hospira uk limited - octreotide acetate - solution for injection - 0.5 mg/ml - somatostatin and analogues

OCTREOTIDE 100 Microgram/ML Solution for Injection Իռլանդիա - անգլերեն - HPRA (Health Products Regulatory Authority)

octreotide 100 microgram/ml solution for injection

fresenius kabi limited - octreotide acetate - solution for injection - 100 microgram/ml - somatostatin and analogues